RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
  Dementia
   Alzheimer's
  Parkinson's
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Alzheimer's Channel

subscribe to Alzheimer's newsletter
Latest Research : Aging : Dementia : Alzheimer's

   EMAIL   |   PRINT
Omega-3 fatty acid supplements may slow cognitive decline

Oct 11, 2006 - 4:48:00 AM , Reviewed by: Priya Saxena
“The mechanisms by which omega-3 fatty acids could interfere in Alzheimer’s disease pathophysiologic features are not clear, but since anti-inflammatory effects are an important part of the profile of fish oils, they are conceivable also for Alzheimer’s disease”

 
[RxPG] Omega-3 fatty acid supplements may slow cognitive decline in some patients with very mild Alzheimer’s disease, but do not appear to affect those with more advanced cases, according to results of a clinical trial published in the October issue of Archives of Neurology, one of the JAMA/Archives journals.

Alzheimer’s disease is a severely debilitating condition that affects thinking, learning and memory, beginning with declines in episodic memory (including memory about events in one’s own life), according to background information in the article. Medications are available to treat the symptoms, but these drugs do not affect the underlying cause and progression of the disease. Several studies have shown that eating fish, which is high in omega-3 fatty acids, may protect against Alzheimer’s disease, leading researchers to question whether supplements could have similar effects.

Yvonne Freund-Levi, M.D., Karolinska Institutet, Stockholm, Sweden, and colleagues compared the effects of supplements containing two omega-3 fatty acids with placebo in 204 patients with Alzheimer’s disease, 174 of whom completed the entire study. For six months, 89 patients (51 women and 38 men) took 1.7 grams of docosahexaenoic acid (DHA) and .6 grams of eicosapentaenoic acid (EPA), while 85 patients (39 women and 46 men) took placebo. For an additional six months, both groups took the omega-3 fatty acids. Patients had physical examinations, which included blood tests and blood pressure measurement, and took cognitive tests at the beginning of the study and at the six- and 12-month marks.

After six months, there was no difference in the rate of cognitive decline between the two groups. However, among a subgroup of 32 patients with very mild cognitive impairment at the beginning of the study, those who took the fatty acids experienced less decline in six months compared with those who took placebo. Among those who took placebo during the first six months, decline decreased during the second six months, when they also began taking the omega-3 supplements. The supplements appeared safe and well-tolerated, with no change in blood pressure or blood test results other than a higher ratio of fatty acids in the blood.

“The mechanisms by which omega-3 fatty acids could interfere in Alzheimer’s disease pathophysiologic features are not clear, but since anti-inflammatory effects are an important part of the profile of fish oils, they are conceivable also for Alzheimer’s disease,” the authors write. This could potentially explain why effects were seen only in those with very early-stage disease—recent evidence suggests that there is a critical period two or more years before patients develop dementia when levels of chemicals that signal the presence of inflammation are elevated. “It is possible that when the disease is clinically apparent, the neuropathologic involvement is too advanced to be substantially attenuated by anti-inflammatory treatment.”

The authors also point out that “these findings cannot serve as a basis for general recommendations for treatment of Alzheimer’s disease with dietary DHA-rich fish oil preparations. However, studies in larger cohorts with mild cognitive impairment, including those at risk for Alzheimer’s disease, are needed to further explore the possibility that omega-3 fatty acids might be beneficial in halting initial progression of the disease.”



Publication: October issue of Archives of Neurology, one of the JAMA/Archives journals
On the web: Arch Neurol. 2006;63:1402-1408 

Advertise in this space for $10 per month. Contact us today.


Related Alzheimer's News


Subscribe to Alzheimer's Newsletter

Enter your email address:


 Additional information about the news article
This study was supported by Pronova Biocare A/S and by grants from the Funds of Capio, Gamla Tjänarinnor, Swedish Alzheimer Foundation, Odd Fellow, Swedish Society of Physicians and Lion’s Sweden. Dr. Palmblad has received travel grants from Pronova Biocare A/S. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)